Ernexa Therapeutics Inc. (ERNA)Healthcare | Biotechnology | Cambridge, United States | NasdaqCM
4.57 USD
-0.10
(-2.135%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 4.48 -0.09 (-0.090%) ⇩ (Aug. 28, 2026, 7:44 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 1:50 a.m. EDT
The immediate narrative is driven by a dramatic 60% intraday surge fueled by positive preclinical data for its ovarian cancer therapy, creating a classic 'dead cat bounce' scenario for a biotech stock in freefall. While the technicals show a sharp recovery from the $3.18 lows, the underlying reality is stark: the company has endured four consecutive years of negative annual returns, with the trailing twelve months seeing a catastrophic 94.6% drop in share price. This multi-year structural decline suggests the market has thoroughly priced out the current business model, rendering the recent volatility a speculative gamble rather than a sustainable trend. Fundamentally, the picture is dire; the company is burning through cash with significant operating losses, negative returns on equity, and no path to profitability visible in the forward estimates. With a reverse stock split looming and zero dividend history, there is no safety net for investors. The recent news flow indicates a temporary refocusing on clinical milestones, but without a proven track record of commercial success or a fortress balance sheet, the long-term outlook remains deeply bearish. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.277826 |
| AutoARIMA | 0.277827 |
| MSTL | 0.299756 |
| AutoTheta | 0.359523 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 24% |
| H-stat | 16.14 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.298 |
| Excess Kurtosis | -1.09 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 10.906 |
| Market Cap | 5,330,142 |
| Forward P/E | -0.48 |
| Beta | 2.56 |
| Previous Name | NTN Buzztime, Inc |
| Website | https://www.ernexatx.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.85850745 |
| Address1 | 1,035 Cambridge Street |
| Address2 | Suite 18A |
| All Time High | 8,625,000.0 |
| All Time Low | 3.18 |
| Ask | 5.97 |
| Ask Size | 2 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 38,830 |
| Average Daily Volume3 Month | 480,132 |
| Average Volume | 480,132 |
| Average Volume10Days | 38,830 |
| Beta | 2.562 |
| Bid | 3.4 |
| Bid Size | 2 |
| Book Value | 2.734 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.57 |
| Current Ratio | 2.01 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 4.9899 |
| Day Low | 4.57 |
| Debt To Equity | 10.906 |
| Display Name | Ernexa Therapeutics |
| Earnings Timestamp End | 1,755,288,000 |
| Earnings Timestamp Start | 1,754,942,400 |
| Ebitda | -11,691,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.238 |
| Enterprise Value | 2,782,118 |
| Eps Forward | -9.6 |
| Eps Trailing Twelve Months | -0.41 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 5.1582 |
| Fifty Day Average Change | -0.5881996 |
| Fifty Day Average Change Percent | -0.114031956 |
| Fifty Two Week Change Percent | -85.850746 |
| Fifty Two Week High | 71.5 |
| Fifty Two Week High Change | -66.93 |
| Fifty Two Week High Change Percent | -0.9360839 |
| Fifty Two Week Low | 3.18 |
| Fifty Two Week Low Change | 1.3900001 |
| Fifty Two Week Low Change Percent | 0.43710694 |
| Fifty Two Week Range | 3.18 - 71.5 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 683,472,600,000 |
| Float Shares | 1,216,211 |
| Forward Eps | -9.6 |
| Forward P E | -0.47604167 |
| Free Cashflow | -5,929,125 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 5 |
| Fullday Change | -0.0997 |
| Fullday Change Percent | -2.13504 |
| Fullday Price | 4.48 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.29824 |
| Held Percent Institutions | 0.021760002 |
| Implied Shares Outstanding | 1,166,333 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,777,852,800 |
| Last Split Factor | 1:25 |
| Long Business Summary | Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts. |
| Long Name | Ernexa Therapeutics Inc. |
| Market | us_market |
| Market Cap | 5,330,142 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_24349026 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-08-28 |
| Net Income To Common | -12,274,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 5,446,425 |
| Number Of Analyst Opinions | 1 |
| Open | 4.76 |
| Operating Cashflow | -8,836,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 617 798 6700 |
| Post Market Change | -0.09000015 |
| Post Market Change Percent | -1.9693687 |
| Post Market Price | 4.48 |
| Post Market Time | 1,787,960,699 |
| Prev Name | NTN Buzztime, Inc |
| Previous Close | 4.6697 |
| Price Hint | 4 |
| Price To Book | 1.6715436 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.743 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.0997 |
| Regular Market Change Percent | -2.13504 |
| Regular Market Day High | 4.9899 |
| Regular Market Day Low | 4.57 |
| Regular Market Day Range | 4.57 - 4.9899 |
| Regular Market Open | 4.76 |
| Regular Market Previous Close | 4.6697 |
| Regular Market Price | 4.57 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 26,226 |
| Return On Assets | -1.05565 |
| Return On Equity | -3.2072198 |
| Sand P52 Week Change | 0.1966995 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 1,166,333 |
| Shares Percent Shares Out | 0.0211 |
| Shares Short | 24,656 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 14,740 |
| Short Name | Ernexa Therapeutics Inc. |
| Short Percent Of Float | 0.0336 |
| Short Ratio | 0.02 |
| Source Interval | 15 |
| State | MA |
| Symbol | ERNA |
| Target High Price | 30.0 |
| Target Low Price | 30.0 |
| Target Mean Price | 30.0 |
| Target Median Price | 30.0 |
| Total Cash | 5,028,000 |
| Total Cash Per Share | 3.08 |
| Total Debt | 349,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.41 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 14.10765 |
| Two Hundred Day Average Change | -9.537649 |
| Two Hundred Day Average Change Percent | -0.6760622 |
| Type Disp | Equity |
| Volume | 26,226 |
| Website | https://www.ernexatx.com |
| Zip | 2,141 |